{"id":"placebo-for-selegiline","safety":{"commonSideEffects":[{"rate":null,"effect":"Placebo response (symptom improvement without active drug)"}]},"_chembl":{"chemblId":"CHEMBL1200904","moleculeType":"Small molecule","molecularWeight":"223.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inactive substance administered in controlled trials to establish a baseline for comparison against the active investigational drug (in this case, Selegiline). Any therapeutic benefit observed in placebo recipients is attributed to natural disease progression, regression to the mean, or psychological expectation effects. This allows researchers to isolate the true efficacy of Selegiline by comparing outcomes between placebo and active treatment groups.","oneSentence":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials to measure the baseline response independent of active drug treatment.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:25.819Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 trial for mood and anxiety disorders (Selegiline comparison)"}]},"trialDetails":[{"nctId":"NCT00013585","phase":"PHASE2","title":"Safety and Effectiveness of the Selegiline \"Patch\" for Decreased Mental Function in HIV Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Cognition Disorders, HIV Infections","enrollment":127},{"nctId":"NCT00439413","phase":"PHASE2","title":"Selegiline for Smoking Cessation - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2007-06","conditions":"Nicotine Dependence","enrollment":246},{"nctId":"NCT00218517","phase":"PHASE2","title":"Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2005-03","conditions":"Marijuana Abuse","enrollment":19},{"nctId":"NCT00032929","phase":"PHASE3","title":"Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-03","conditions":"Cocaine-Related Disorders","enrollment":269},{"nctId":"NCT01330030","phase":"PHASE2","title":"Selegiline Patch for Treatment of Nicotine Dependence","status":"COMPLETED","sponsor":"Stanford University","startDate":"2005-07","conditions":"Tobacco Use Disorder","enrollment":243},{"nctId":"NCT01912391","phase":"PHASE3","title":"Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder","status":"COMPLETED","sponsor":"Mood and Anxiety Research, Inc","startDate":"2012-10","conditions":"Borderline Personality Disorder","enrollment":30},{"nctId":"NCT00129311","phase":"PHASE2","title":"Usefulness of Selegiline as an Aid to Quit Smoking - 1","status":"COMPLETED","sponsor":"Yale University","startDate":"2004-07","conditions":"Tobacco Use Cessation","enrollment":101},{"nctId":"NCT00531947","phase":"PHASE4","title":"Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression","status":"COMPLETED","sponsor":"Somerset Pharmaceuticals","startDate":"2007-07","conditions":"Major Depressive Disorder","enrollment":308},{"nctId":"NCT01495195","phase":"PHASE2","title":"Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior","status":"COMPLETED","sponsor":"Midwest Biomedical Research Foundation","startDate":"2012-02","conditions":"Cocaine Use Disorders","enrollment":12},{"nctId":"NCT00390923","phase":"NA","title":"Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence","status":"TERMINATED","sponsor":"Centre for Addiction and Mental Health","startDate":"2007-07","conditions":"Nicotine Dependence","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":220,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (for Selegiline)","genericName":"Placebo (for Selegiline)","companyName":"Mood and Anxiety Research, Inc","companyId":"mood-and-anxiety-research-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials to measure the baseline response independent of active drug treatment. Used for Control arm in Phase 3 trial for mood and anxiety disorders (Selegiline comparison).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}